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Cervical carcinoma (CC) is one of the most common tumours
affecting women world-wide, both in incidence and mortality,
with approximately 471 000 new cases diagnosed annually
(Cannistra and Niloff, 1996). This tumour is associated to some
specific types of human papillomaviruses (HPV), particularly
types 16, 18, 33 and 42 (zur Hausen, 1994; Howley, 1995; Shah
and Howley, 1995). Recent data suggest that all cases are HPV-
positive (Bosch et al, 1995). The peak incidence of the disease
occurs in women over 40 years of age; however, the peak inci-
dence for HPV infection is in the 20s, therefore there is a long
latency period between the time of HPV infection and cancer
appearance. Despite the infection by HPV, the course of the
disease has many aspects that remain unsolved (Braly, 1996; Lazo,
1988a). Among these issues are how a productive infection
becomes silent and long-lasting, or what makes most HPV-
induced cervical lesions reversible (Cannistra and Niloff, 1996),
both are likely to be a consequence of the host immunological
situation. And most important, what marks the transition to malig-
nancy of the HPV-containing cell and its progression to invasive
carcinoma. The course of this tumour is similar to other cancers,
with the difference of having a virus as a pathogenic agent.
Therefore, in cervical carcinoma, some aspects of the pathogenesis
might be influenced by the viral presence. In experimental
systems, the presence of a high-risk HPV is not sufficient to
induce transformation and tumour progression (Chen et al, 1993).
This observation was further supported by in vitro studies of HPV-
containing human keratinocytes which need several chromosomal
alterations in order to become immortalized and transformed
(Montgomery et al, 1995; Uejima et al, 1995). But, as a cancer,
CC should also have a sequential accumulation of genetic damage
that is selected as the tumour phenotype progresses.
Cancer is a multigenic disease, mostly somatic (Kinzler and
Vogelstein, 1996, 1998; Lengauer et al, 1998). Cancer-related
genes can fall in two major categories: oncogenes that have a
dominant effect and tumour suppressor genes with a recessive
phenotype. Recurrent chromosomal alterations are a hallmark of
most tumour types and they are markers for the presence of an
oncogenesis-related gene (Rabbitts, 1994, 1997). Chromosomal
translocations are the prototype of recurrent aberrant genetic
damage (Mitelman et al, 1997), and their result is the activation of
a gene in cis, the silencing of a gene, or the formation of a novel
protein produced by the fusion of coding sequences located on
each chromosome (Sánchez-García, 1997). The biological conse-
quence of the translocation, by either mechanism, is either to
change the proliferation or differentiation properties of the
affected cell (Sánchez-García, 1997). Other recurrent changes
include point mutations, gene amplifications and losses of
heterozygosity (LOH). However, it is likely that the genes impli-
cated in each type of cancer are different as individual genes, but
they all may have in common belonging to the same general type
of genes, reflecting the particular phenotypic aspect where they are
implicated, and the stage of cancer development where they inter-
vene, which is likely to be the reason for their selection
(Tomlinson et al, 1996; Tomlinson and Bodmer, 1999).
Within the pathogenesis of cervical carcinoma, the role played
by HPV might be conceptually similar to the role of a genetic
predisposing mutation which will favour the appearance of the
tumour in a specific organ. The subset of HPV-infected cells
mimic a group of cells that have the functional equivalent of
mutations in TP53 and RB because of the consequence of their
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interaction with viral gene products (Banks et al, 1995; Kubbutat
and Vousden, 1996). Therefore, in the pathogenesis of cervical
carcinoma we can identify three major factors. Two of them are
related to the HPV presence, the effects of viral E6 and E7
proteins, and the consequences of HPV DNA integration in the
cellular genome. The third factor is the accumulation of cellular
genetic damage, not related to HPV, needed for tumour develop-
ment (Tomlinson et al, 1996; Lengauer et al, 1998).
CONSEQUENCES OF INTEGRATION ON VIRAL
GENES
Viral DNA integrated into host genome is found in all cases of
cervical carcinoma (Bosch et al, 1995), their metastasis and deriv-
ative cell lines (Cullen et al, 1991). This viral DNA integration is
in itself a mutation with consequences both on viral and cellular
genome. Cells carrying integrated viral DNA grow better in vitro,
and integration has been correlated with a poor prognosis, and
development of resistance to treatment (Unger et al, 1995; Vernon
et al, 1997; Kalantari et al, 1998). In the case of cervical carcinoma
the integration of viral DNA can contribute to two aspects where
HPV is implicated in the CC phenotype. The different conse-
quences of HPV integration either on viral or cellular genome,
reflecting the common characteristics of independent CC, are
outlined in Table 1.
From the viral perspective there is only a small deletion of
DNA, rarely being more than three kilobases, and retention of
specific viral genes. The integrated HPV DNA is linearized
between the E1 and L1 genes, in such a way that the viral regula-
tory region and the E6 and E7 genes are expressed from viral
promoters, but with a different regulation, in which cellular factors
might play an important role (Gloss et al, 1989; Rosl et al, 1991;
Bartsch et al, 1992; O’Connor et al, 1996). From these hybrid
viral-cellular aberrant RNA messages, normal E6 and E7 proteins
are synthesized. There is also the loss, by break or deletion, of the
viral E2 gene, that normally functions as a positive and/or negative
regulator of transcription. Furthermore, the cellular DNA might
have undergone complex rearrangements and deletions which are
sometimes very large (Gallego and Lazo, 1995; Bauer-Hoffman
et al, 1996; Gallego et al, 1997).
Table 1 Characteristics of HPV DNA integration in host genome
On viral gene structure
Viral DNA is linearized between L1 and L2, the size of deleted viral DNA is
variable
Retention of regulatory region (LCR or URR)
Retention of E6 and E7 genes
Inactivation E2 transcriptional regulator
Loss or damage of all other viral genes: E1, L1 and L2
On viral gene expression
E6 and E7 expression modulated by flanking cellular sequences or cellular
transcription factors
E6 and E7 transcripts have altered message stability
E6 and E7 expressed from hybrid viral cellular message produce normal
proteins
On cellular genome
Initial integrations might be random resulting from recombination
Selected integrations are near fragile sites or oncogenes
Integration is recurrent at some locations: 8q24 and 12q14–15
Frequent deletion of cellular sequences, the rearrangement is complex
Altered cellular gene expression as consequence of nearby integration: 
N-MYC, JUN-B
Cell cycle phase
G1
HPV-E6
HPV-E7
E2F Rb
Rb E7
Rb
E2F
+ -
p53
E6 -p53
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p53     Ubiquitin
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Ubiquitin
Ubiquitin +
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Figure 1 Dual effect of HPV E6 and E7 proteins on the cell cycle. Possible mechanism by which HPV E6 and E7 protein can functionally mimic a state of
deficiency of p53 and Rb tumour suppressor proteins. The viral proteins promote the ubiquitin-mediated degradation of both tumour suppressor proteins
releasing brakes of cell cycle progression and facilitating the expression of genes also needed for completion of the cell cycle2010 PA Lazo
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Effects of viral E6 and E7 proteins
The effects of E6 and E7 viral genes have been extensively studied
(Kubbutat and Vousden, 1996). These two viral genes are always
retained and overexpressed in CC, and therefore are supposed to
contribute to the tumour phenotype. The E6 and E7 proteins have
been shown to induce immortalization of different cell types, such
as fibroblasts (Pirisi et al, 1987) and human keratinocytes (Smith
et al, 1992). In keratinocytes, immortalized with HPV and
expressing E6 and E7, there is an alteration of the balance between
proliferation and cell death (Smith et al, 1992), which suggests that
the functions of E6 and E7 are to expand a cell population because
of their effect on immortalization, probably as a consequence of
their effects on apoptosis (Thomas et al, 1996; Iglesias
et al, 1998; Stoppler et al, 1998). In order for these proteins to
induce cellular transformation, by in vitro parameters, they require
the cooperation of other genes (Kubbutat and Vousden, 1996),
such as the co-transfection with the H-ras oncogene (Schneider
et al, 1991).
The E6 protein interacts with the p53 tumour suppressor protein
(Werness et al, 1990) theoretically resulting in the functional
sequestration of p53 (Figure 1) and targeting it for degradation via
the ubiquitin-dependent proteolytic pathway (Thomas et al, 1996).
The binding of E6 to p53 might thus contribute to accumulate
additional mutations by allowing progression through the cell
cycle before DNA has been repaired, by altering the control
checkpoint for DNA integrity in the G1 phase before entering
the S phase of the cell cycle. An additional consequence could be
the inhibition of apoptosis by the partial effect of p53 levels and
of pRb.
The HPV E7 protein interacts with either pRb and the p107- or
p130-related proteins (Figure 1). This interaction dissociates these
proteins from the transcription factor E2F. The free E2F factor
can activate transcription of genes that will promote cell cycle
progression and cell proliferation (Kubbutat and Vousden, 1996).
E7 can also interact with cellular transcription factors such as
AP-1 (Antinore et al, 1996).
It is important to take into account that high levels of E6 and E7
expression can also be achieved from viral DNA in its extrachro-
mosomal form, therefore in CC there must be additional factors
that contribute to the final tumour phenotype and which might be
selected, consistent with the long time that occurs between initial
infection and tumour appearance. Curiously, benign tumours
induced by other HPV types have a higher cell number and shorter
tumour formation time than the malignant tumours. Furthermore,
other oncogenic viruses, such as adenovirus and SV40, have
proteins which interact with p53 and pRb even more efficiently
than HPV proteins, yet they do not induce tumours in humans.
Therefore, the effects of E6 and E7 may be mediated by a mecha-
nism not yet identified.
Inactivation of viral E2 gene by integration
The viral E2 gene codes for two proteins with a transcriptional
regulatory function. The E2 protein has a transcriptional activation
domain in the N-terminus and a DNA binding domain in its
C-terminus. The E2 gene can be expressed in two forms, a
complete protein that is a positive regulator, and a protein with
only the DNA binding domain that functions as a repressor
(Dowhanick et al, 1995). The full-length E2 protein induces cell
cycle arrest in the S phase, thus allowing the replication of viral
DNA, but at the same time resulting in an increase in cellular DNA
which might be implicated in the generation of the aneuploidy
observed in CC (Dowhanick et al, 1995; Frattini et al, 1997). Thus
the normal E2 increases the viral load of the infected cell (early
lesions) and might alter its chromosome number. In integrated
viral DNA there is a loss of both types of E2 proteins. After
Table 2 Human papillomavirus chromosome integration regions and tumour phenotypes associated to these regions
HPV type Chromosomal region Tumour phenotypes
18 2p24 Neuroblastoma, lung carcinoma
16 2q34–35 Sarcomas, breast adenocarcinoma, non-Hodgkin’s
lymphoma
16 3p14.2 Many types of carcinomas
18 3p21–22 Non-Hodgkin’s lymphoma, pleomorphic adenoma,
adenocarcinoma (kidney, ovary, colorectal), lung
carcinoma
16 3q25 Ovarian carcinoma, non-Hodgkin’s lymphoma
18 5p11–15 Adenocarcinoma (breast, kidney, lung, pancreas, stomach),
AML
18 8q22 AML
16,18 8q24 Burkitt’s lymphoma, ALL,
malignant lymphoma, familial renal carcinoma,
chondrosarcomas
18 9q31–q34 AML, CML, ALL
16,18 12q14–15 Melanoma, lipoma, liposarcoma, glioma, leiomyosarcoma,
pleomorphic adenoma, T-cell lymphoma, hamartoma
16 13q21–31 AML, ALL, CML
16 15q14–15 AML
16 19p13.2 AML, ALL, Ewing’s sarcoma, melanoma
18 22q12–q13 Neuroepithelioma, meningioma, Ewing’s sarcoma, CML,
abnormal neuroblastoma
AML, acute myeloid leukaemia; ALL, acute lymphoblastic leukaemia; CML, chronic myeloid leukaemiaThe molecular genetics of cervical carcinoma 2011
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integration, the removal of this brake, will allow the expansion of
cells carrying genetic anomalies of different types. The loss of E2
confers better growth properties to the cell (Jeon and Lambert,
1995; Jeon et al, 1995). The clinical relevance of the inactivation
of the E2 gene was demonstrated by the analysis of 46 patients
with HPV DNA integrated and with disruption of the E2 viral
gene. This E2 damage was associated with poor prognosis and a
significantly shortened disease-free survival of the patient (Unger
et al, 1995; Vernon et al, 1997; Kalantari et al, 1998).
Additional evidence for a contributing effect of the E2 loss of
function comes from different studies. In cells transfected with
HPV16, the viral DNA was integrated in the genome of the host
cell, and these cells acquired a growth advantage that could not be
explained by the known effects of other retained viral genes, E6
and E7 (Jeon et al, 1995). Later on, it was demonstrated that the
reintroduction of a normal E2 protein, from HPV16 or HPV18, in
HeLa cells, suppressed the cell growth of these cells (Dowhanick
et al, 1995). For this effect to take place, both the transactivating
and DNA binding domains of this E2 protein have to be intact
(Dowhanick et al, 1995).
Lack of homology between viral and cellular DNA at
integration sites and location of HPV DNA integration
sites
One of the characteristics of cancer is the presence of recurrent
chromosomal alterations associated to a specific type of tumour.
These usually take the form of translocations, but also include
amplifications, deletions and point mutations. These alterations
are rather well characterized in human lymphoid tumours.
Whereas in human solid tumours, their characterization lags
behind because of the characteristics of the starting material, this
has not been an obstacle for the detection of such recurrent chro-
mosomal alteration in most types of cancer (Mitelman et al, 1997).
In this context we can consider the integration of viral DNA in the
cellular genome as a type of recurrent alteration in cancers associ-
ated to HPV, CC being the most extensively studied.
Viral DNA integration is irreversible genetic damage that could
affect cellular genes. Several integration sites and their corre-
sponding normal target sequences have been cloned and studied
(El Awady et al, 1987; Lazo, 1988b; Choo et al, 1990; Gallego
et al, 1997). Sequence comparisons do not detect any significant
homology either between viral and target cellular DNA, or among
the different cellular target regions. This lack of homology
suggests that it is the result of non-homologous recombination
between cellular and viral DNA. It is likely that there might be
some preference for chromatin regions where cellular DNA might
be more accessible (Popescu et al, 1990). In this context it is
important to note that several integration regions are in chromo-
somal regions identified as fragile sites (Table 2) (Durst et al,
1987; Popescu et al, 1990; Lazo et al, 1992; Zimonjic et al, 1994).
Direct evidence for integration within a known fragile site has
recently been reported for the integration of HPV16 at 3p14.2
(Wilke et al, 1996), where FRA3B is located, within the FHIT
gene (Zimonjic et al, 1997). In a population of infected cells that
individually might have viral DNA integrated in different chromo-
some regions, those that have integrated the viral DNA in a region
that confers a specific phenotype could be selected, with the final
result of a non-random pattern from the point of view of the
tumour. If that is the case, integration sites in tumour samples
should have the integrated viral DNA in regions where there are
genes or genetic alterations which most likely have already been
associated to some tumour phenotype properties because this
phenotype, despite individual tumour differences, is common in
general terms to many tumour types.
The locations of mapped HPV integration sites in cervical carci-
noma are shown in Table 2. All coincide with chromosome regions
already linked to the tumour phenotype, mainly by translocations.
It is worth noting that, despite the small number of cases studied,
two chromosomal regions, 8q24 (Durst et al, 1987; Lazo, 1988b;
Couturier et al, 1991) and 12q14–15 (Sastre-Garau et al, 1995;
Lopez-Borges et al, 1998), are recurrently affected by both HPV-
16 and HPV-18 DNA integrations. Furthermore, some genes have
been shown to be directly affected by integrated HPV DNA, such
as FHIT in 3p14–21 (Wilke et al, 1996), MYC in 8q24 (Durst et al,
1987; Lazo, 1988b; Couturier et al, 1991) and JUN-B in chromo-
some 19p13.2 (Choo et al, 1995).
RECURRENT CELLULAR GENETIC
ALTERATIONS IN CC
Cervical lesions must accumulate an increasing number of muta-
tions as they progress towards malignancy and invasion.
Therefore, the identification of recurrent chromosomal alterations
is of utmost importance for the understanding of the biology of
this cancer. The genetic alterations in CC might be either a conse-
quence of biological selection for specific chromosome locations
containing integrated HPV DNA or result from other alterations
that are recurrently affected in this tumour. The recurrent genetic
alterations might take several forms such as translocations, point
mutations, amplifications, viral DNA integrations, mutator pheno-
types or LOH. The LOH means that a particular DNA region has
been lost, and therefore, if this loss is recurrent in a significant
number of cases of a particular tumour type we can conclude that
this chromosome region plays a role in that tumour, and is selected
because of it (Tomlinson et al, 1996; Tomlinson and Bodmer,
1999). LOH is generally thought of as an intermediate step in the
inactivation of tumour suppressor genes, such as p53 or RB, which
requires the inactivation of both alleles in order to display their
phenotype. However, in most cases, the LOH reflects a hemizy-
gous situation and its effect might be a dose effect rather than inac-
tivation of a tumour suppressor gene, although both share a
common mechanism of inactivation, and hence of detection, of the
loss of genetic material. A particular situation might be repre-
sented by the possible existence of different alleles of tumour
susceptibility gene, if one of the alleles is more effective than
others, there might be a loss of the less effective allele, thus domi-
nating the predisposing allele in these tumours.
LOH analysis has been extensively applied to CC leading to the
identification of several chromosomal regions that are recurrently
affected in this tumour (Table 3).
LOH at 3p and the FHIT gene in CC
The 3p region has been implicated in ovarian cancer, breast cancer,
testicular cancer, lung cancer and renal cell carcinoma, strongly
suggesting the presence of a tumour suppressor gene in the region.
In CC, a broad region, 3p12–24, was identified as a target for
LOH. The combined data show that LOH occurs at an average
frequency of 48% (Table 3), although it varies from study to study
depending on the number of markers used (Jones and Nakamura,
1992; Kohno et al, 1993; Karlsen et al, 1994; Mitra et al, 1994a;2012 PA Lazo
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Mullokandov et al, 1996; Ku et al, 1997; Larson et al, 1997; Chu et
al, 1998; Huettner et al, 1998). These LOH were detected in both
squamous cell carcinomas and adenocarcinomas. In some studies
the frequency appears to be higher in squamous cell carcinomas
(68%) than in adenocarcinomas (42%) (Larson et al, 1997). LOH
in 3p might be an indicator of tumour progression (Table 2), since
its frequency increases from 25% in FIGO stage I cases to 100% in
stage IV cases (Larson et al, 1997). Among the genes from this
chromosome region ruled out to be affected by LOH are APEH,
D8,  GNA12B,  ZNF35,  RARB,  THRB and  RAF1 (Kohno et al,
1993).
Several studies agree that within the region 3p14–p22 there are
two subregions where the LOH are concentrated, and frequently
both are altered in the same tumour. These two regions are 3p14.2
and 3p21 (Kohno et al, 1993; Karlsen et al, 1994; Mitra et al,
1994a; Larson et al, 1997; Chu et al, 1998). These data suggest
that two tumour suppressor genes are likely to be located in this
chromosome region (Huettner et al, 1998; Kersemaekers et al,
1998a).
Recently the FHIT gene has been identified within the chromo-
some region 3p14.2, which is altered in several types of tumours,
such as lung (Sozzi et al, 1996), breast (Hayashi et al, 1997) and
oesophageal carcinomas (Zou et al, 1997), but not in others, such
as colon carcinoma (Thiagalingam et al, 1996). These alterations
are detected at the cDNA level in the form of exon losses. The
FHIT gene spans more than 1 Mb and comprises the FRA3B
fragile site (Zimonjic et al, 1997). It is important to note that inte-
gration of HPV16 occurred directly at the FRA3B fragile site
when using HPV integration as a marker for potential oncogenic
loci in HPV16 immortalized keratinocytes (Wilke et al, 1996).
This integration occurred between exons 4 and 5 (Zimonjic et al,
1997). The FHIT gene has been specifically studied in cervical
carcinomas (Greenspan et al, 1997; Chu et al, 1998; Muller et al,
1998; Yoshino et al, 1998). Aberrant FHIT transcripts were
detected in seven out of 11 (63%) CC cell lines and in 35 out of 74
(47%) primary cervical carcinomas of different types and stages
(Muller et al, 1998). The aberrant transcripts usually are coex-
pressed together with a normal transcript. This loss of normal tran-
script was correlated with a significant loss of FHIT protein by
inmmunohistochemistry. In 25 out of 33 primary tumours there
was no detectable FHIT protein, while high levels were detected in
normal non-neoplastic squamous and glandular cervical epithe-
lium (Greenspan et al, 1997). In another study of 57 cases, aberrant
FHIT mRNA was detected in 9/29 (31%) of the cases, but in
normal tissues similar aberrant transcripts were detected in 12/31
of the cases. Therefore it appears that FHIT exon skipping may not
be a specific property of the tumour cell (Chu et al, 1998). The
FHIT gene is not a typical tumour suppressor gene (Le Beau et al,
1998), and the mechanism by which it might contribute to the
tumour phenotype is not known (Mao et al, 1996).
In the 3p21 region the affected gene is not known. This region
has the hMLH1 gene, responsible for a mutator phenotype. This
gene does not show LOH and is unlikely to be mutated in CC
because the frequency of the mutator phenotype in CC is one order
of magnitude lower than the LOH frequency. Another candidate
gene in the region is b-catenin, but its implication in CC has also
been ruled out (Kersemaekers et al, 1998a). LOH at 3p21 appears
to correlate with high mitotic activity (Kersemaekers et al, 1998a).
The importance of chromosome 3 region in CC is consistent
with previous studies in experimental systems. Human
Table 3 Recurrent LOH in cervical carcinomas
Chromosome No. of cases % References
region (positive/informative)
3p14.1–p22 186/391 48 Yokota et al, 1989; Jones and Nakamura, 1992;
Kohno et al, 1993; Karlsen et al, 1994;
Mitra et al, 1994a; Mullokandov et al, 1996;
Ku et al, 1997; Larson et al, 1997;
Chu et al, 1998; Huettner et al, 1998;
Kersemaekers et al, 1998b
4p16 27/66 40 Hampton et al, 1996;
Mullokandov et al, 1996;
Kersemaekers et al, 1998b
4q21–35 23/72 32 Mitra et al, 1994a;
Mullokandov et al, 1996;
Kersemaekers et al, 1998b
5p13–15 20/117 17 Ku et al, 1977; Mitra et al, 1994a;
Mullokandov et al, 1996;
Kersemaekers et al, 1998b
6p21.3–22 60/147 41 Mitra et al, 1994a; Mullokandov et al, 1996;
Huettner et al, 1998; Kersemaekers et al, 1998b
11p15 12/43 28 Mitra et al, 1994a;
Mullokandov et al, 1996
11q23 73/188 38 Hampton et al, 1994; Bethwaite et al, 1995;
Mullokandov et al, 1996; Huettner et al, 1998;
Kersemaekers et al, 1998a, 1998b
17p13.3 50/208 24 Fujita et al, 1992; Kaelbing et al, 1992;
Mitra et al, 1994a; Park et al, 1995;
Mullokandov et al, 1996; Ku et al, 1997;
Kersemaekers et al, 1998b
18q12.2–22 18/75 24 Mitra et al, 1994a;
Mullokandov et al, 1996;
Kersemaekers et al, 1998bThe molecular genetics of cervical carcinoma 2013
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keratinocytes immortalized with HPV-16 DNA show LOH at 3p.
The tumorigenicity of these cells in nude animals correlated very
well with instability and loss of genetic material from human chro-
mosome 3p (Montgomery et al, 1995; Steenbergen et al, 1996),
10p, 11q and 18q regions (Montgomery et al, 1995; Steenbergen
et al, 1995, 1996). If these regions are the same as those showing
LOH in primary tumour samples, they might be very useful for the
identification of the specific genes involved. Moreover, LOH in
3p13–22 was also detected in ten out of 16 (62%) CC cell lines,
which is consistent with the data obtained from primary tumours
(Larson et al, 1997).
Chromosome 4 in CC
There is experimental evidence suggesting that human chromo-
some 4 might be important in CC. The introduction of chromo-
some 4 into HeLa cells conferred a senescence phenotype (Ning
et al, 1991). Furthermore, the most common chromosome aberra-
tion is the detection of an isochromosome, i(4), in CC (Atkin et al,
1989). Later, LOH studies identified at least two regions that are
frequently involved in this tumour (Table 3). One of them, in the
short arm, 4p16, is consistent in all studies. The second, in the long
arm, has been mapped to a larger area, 4q21–35, depending on the
markers used. But the general conclusion is that two genes on this
chromosome contribute to the cervical carcinoma phenotype
(Hampton et al, 1996; Kersemaekers et al, 1998b).
The short arm of chromosome 5 in CC
The first evidence indicating that chromosome 5 might be impli-
cated in CC was detected in the HeLa cell line. This cell line has
an isochromosome 5p with integrated HPV18 (Popescu et al,
1987). Furthermore, the cytogenetic analysis of 43 cervical carci-
nomas, stages IIb–IV, also detected the presence of i(5p) in 75% of
the cases, and frequently there were two copies of this isochromo-
some (Atkin et al, 1989). Later, using comparative genome
hybridization (CGH), amplification of 5p was detected in a large
number of cases, particularly in advanced stages, from IIb to IV
(Heselmeyer et al, 1997), consistent with the cytogenetic
evidence. All these data suggest a dose effect of a gene located on
5p. However, LOH studies on this chromosome have revealed a
low number of affected loci (Mullokandov et al, 1996;
Kersemaekers et al, 1998b).
Chromosome 6 in CC
Several studies have identified a very high incidence (41%) of
LOH in the short arm of chromosome 6p21.3–p25 (Mitra et al,
1994a; Mullokandov et al, 1996; Huettner et al, 1998;
Kersemaekers et al, 1998b). Some groups identify two indepen-
dent regions with LOH, 6p21.3 and 6p24 (Kersemaekers et al,
1998b). Among the candidate altered genes is TNF-a on 6p21.3.
Using markers for this gene, LOH was detected in 17 out of 43
(40%) cases of FIGO stages I and II lesions (Kersemaekers et al,
1998b). Although there is still no functional evidence for the role
of TNF-a in cervical carcinoma, its alteration is likely to make
tumour cells less sensitive to the induction of apoptosis and there-
fore promote their survival (Hueber et al, 1997; Krammer, 1997).
Chromosome 11 in CC
Three lines of work support the importance of human chromosome
11 in cervical cancer, all of them pointing to the presence of a
tumour suppressor gene that plays a fundamental role in this
tumour phenotype. The initial evidence came from somatic cell
genetics. The fusion of HeLa cells (with integrated HPV18) or
SiHa cells (with integrated HPV16), with microcells containing
human chromosome 11, resulted in the generation of cell hybrids
that have lost their tumorigenic properties in nude mice, but if
these hybrids lost the introduced chromosome 11 they regained
their tumorigenic phenotype (Saxon et al, 1986; Koi et al, 1989;
Oshimura et al, 1990). Furthermore, the progression towards
immortalization of human keratinocytes transfected with either
HPV16 or HPV18 was accompanied by allele losses at 11q
(Steenbergen et al, 1996), and cytogenetic studies of cervical
carcinomas detected that chromosome 11 is underrepresented
(Southern and Herrington, 1997).
Two different regions with LOH have been identified in
chromosome 11, one on each arm (Srivasan et al, 1991; Hampton et
al, 1994; Mitra et al, 1994a; Bethwaite et al, 1995; Mullokandov et
al, 1996; Kersemaekers et al, 1998a, 1998b). Two groups detected
LOH in 12 out of 43 cases (28%) in the 11p15 region, but could not
show that the Wilms’ tumour (WT1) suppressor gene is implicated
in these carcinomas (Mitra et al, 1994a; Mullokandov et al, 1996).
Other groups detected LOH in 11q22–24 (Table 3). The region
where this putative tumour suppressor gene might be was narrowed
down to 11q23 (Hampton et al, 1994; Bethwaite et al, 1995;
Mullokandov et al, 1996; Kersemaekers et al, 1998a). LOH at
11q23 has a strong correlation with the presence of an invasive
carcinoma at FIGO stages I and II (Kersemaekers et al, 1998b).
However, it is not known if any of these two regions are the ones
that revert the tumorigenic phenotype of HeLa and SiHa cells.
LOH in chromosome 17 and lack of mutations in p53
Chromosome 17 was the first to attract attention in cervical carci-
noma because it contains the TP53 gene in its p13.3 band, which is
frequently mutated in many types of tumours (Greeblatt et al,
1994). Therefore, several studies have attempted to determine if
this chromosome region is altered. The frequency of LOH at
17p13.3 is 24% (Table 3), and most often did not affect the TP53
locus. Thus, suggesting the candidate tumour suppressor gene in
this region must be different from TP53 (Park et al, 1995),
evidence for this new gene has been recently found in lung cancer
(Konishi et al, 1998). Several studies have also attempted to corre-
late  TP53 mutations with the HPV status of the tumour. p53
appears to be more frequently mutated in HPV-negative tumours,
but this negativity has been questioned since nowadays all
tumours are considered HPV-positive (Bosch et al, 1995). The
frequency of mutation is rather low, less than 10%, in CC (Fujita et
al, 1992; Castren et al, 1998; Helland et al, 1998a) when compared
to mutations in other tumours, such as lung or colon carcinomas
(Greeblatt et al, 1994). This lack of mutations has lent support to
the interpretation that mechanism implicated in these tumours is
likely to be a consequence of the interaction of HPV E6 viral
protein with p53 protein (Figure 1), and by which they could
achieve a biological situation resembling a partial p53 defect.
Overexpression of p53 may be found in cases of CC negative
for HPV (Helland et al, 1998a). The analysis of the expression of
p53 protein in cervical lesions detected a high level of p53 expres-
sion in low-grade SIL lesions and in lesions with HPV 6/11/42
(86%) (Kurvinen et al, 1996). But in high-grade SIL or
HPV16/18-positive lesions the level of p53 was absent or detected2014 PA Lazo
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in only a few cells (Kurvinen et al, 1996). These authors found no
correlation of lesion with mdm2 protein antigen level. In the same
study the bcl2 protein was confined to basal cells in normal epithe-
lium, and in hSIL lesions positive for HPV16/18 bcl2 appeared
located on suprabasal cells (Kurvinen et al, 1996).
Chromosome 18 and 19 recurrent LOH in CC
In two other chromosomes, 18 and 19, LOH have been detected in
two different regions, although these chromosomes have been
studied in less detail. In chromosome 18 LOH within 18q21 region
was detected in 24% of the cases (Table 3), and in a smaller
proportion in 18p11 band, 22 out of 172 cases (12%) (Mitra et al,
1994a; Mullokandov et al, 1996; Huettner et al, 1998;
Kersemaekers et al, 1998b). There is no information regarding the
possible genes affected.
On chromosome 19 there are also two LOH regions, although
their frequency is lower than 20%. LOH has been detected in
19q12–13 (Mullokandov et al, 1996; Huettner et al, 1998;
Kersemaekers et al, 1998b) and 19p13 (Mullokandov et al, 1996;
Huettner et al, 1998; Kersemaekers et al, 1998b), which are the
breakpoints of the two chromosome 19 regions frequently
involved in chromosomal translocations (Mitelman et al, 1997).
Recurrent point mutations in CC
There have been several studies attempting to detect mutations in
genes well known to have point mutations in other tumours,
including  H-RAS,  TP53,  p16INK4A,  p15INK4B RB and other cell
cycle genes. These were tested in both HPV-positive and -negative
cells. Some mutations have been detected in H-RAS (Dokianakis
et al, 1998; Leis et al, 1998). The p15 and p16 genes, both on
chromosome 9p21 and separated by 25 kilobases, do not present
mutations in CC (Kim et al, 1998). However, it is not known if the
p19ARF gene, which shares exons with p16 and which appears to
be the cause of the phenotype previously attributed to p16, is
affected (Kamijo et al, 1997). The data on TP53 are dealt with in
the section on chromosome 17.
Recurrent amplifications and chromosome gain
Gene amplification and chromosome gain are two different mech-
anisms by which a tumour cell can increase a gene dosage. In a
study of 22 protooncogenes in 50 primary untreated squamous cell
carcinomas of the uterine cervix, clinical stages II and III, only 12
(24%) have some amplifications (Mitra et al, 1994a, 1994b).
Fivefold or larger amplifications were found for MYCL1, SEA,
CCND1, BCL1 and GLI genes in one case (2%); HRAS was ampli-
fied in two cases (4%); and ERBB2 in seven cases (14%). SEA,
CCND1 and BCL1 map to band 11q13 and might be within a
unique amplicon. Two of the ERBB2 cases also showed rearrange-
ment of the 17q11.2–12 band, suggesting a possible damage of this
gene. Overexpression of ERBB2 gene has been previously
reported in 60% of the cases studied (Pinion et al, 1991).
ERB2/neu amplification has been observed in other carcinomas,
including breast and ovary (Mitra et al, 1994b). The protoonco-
genes that have been studied and that showed no amplification
were: NMYC, RAF1, KIT, ROS1, EGFR, MDR1, MET, MYC,
INT2, KRAS2, ETS1, WNTI, MDM2, SRC and PDGF.
The uterine cervix has been used to study chromosomal
aberrations during the transition from premalignant to invasive
carcinoma (Heselmeyer et al, 1996). CC has well-defined progres-
sion steps based on cytology that are useful for correlation with
genetic aberrations. These authors studied normal cervical epithe-
lium, mild, moderate and severe dysplasias as well as CC. The first
alteration detected when there is an increase in cell proliferation is
the appearance of tetraploidy. No other recurrent aberration was
observed in the transition from normal to moderate dysplasia. In
one severe dysplasia a gain of 3q (one out of 13) was observed. In
invasive carcinomas a gain of 3q was detected in nine out of ten
cases (90%). Thus, gain of 3q can be considered a late and impor-
tant alteration for the developments of invasive cervical carci-
noma. The smaller common region of amplification has been
reduced to band 3q24–28 (Heselmeyer et al, 1996).
Microsatellite instability and mutator phenotype
Alterations in DNA repair genes result in the accumulation of
mutations, some of which are important for tumour development.
DNA repair genes belong to a family of genes designated as care-
taker genes (Kinzler and Vogelstein, 1998). The phenotype of
mutations in this type of genes is detected by microsatellite insta-
bility (MI). The cell with a defect in any of these genes will invari-
ably progress to develop a cancer (Kinzler and Vogelstein, 1998).
In a study of 89 primary tumours, ten cervical carcinoma cell lines
and 30 loci located on 3p, 4 and 11q were analysed for MI. Three
out of 89 tumours (3.3%) exhibited novel tumour-specific alleles
at 77, 70 and 60% of the loci studied respectively (Larson et al,
1996). Two other tumours also have some MI using additional
markers, bringing the total to 5/89 (5.6%). In this work the impli-
cation of the hMLH1, in 3p21, was ruled out. Also one cell line,
C33A which is negative for HPV, presented this mutator pheno-
type, with new alleles in 30 of 84 markers determined (Larson
et al, 1996). In another study, alterations at eight dinucleotide loci
mapping to six different chromosomes were found in five out of 82
cervical cancers (Helland et al, 1997; Kersemaekers et al, 1998a).
In another 51 cases, mutator phenotypes were detected in four
cases (Ku J-L et al, 1977; Ku W-H et al, 1997). This instability
affected to one or two alleles at one or few loci. The use of semi-
automated fluorescence-based detection allowed the identification
of additional five out of 58 cases showing MI (Hampton et al,
1996). A more recent study has found microsatellite instability in a
larger number of cases, in nine out of 64 cases (14%)
(Kersemaekers et al, 1998a).
Overall, of 344 cases analysed for the presence of the mutator
phenotype, only 28 displayed MI (8%), independently of the type
of allele and number of chromosomes studied (Ku J-L et al, 1977;
Larson et al, 1996; Helland, 1997; Ku W-H et al, 1997), which
represents a small subset of the total number of CC cases.
Multiple genetic changes in CC: combined genetic
alterations in individual tumours
Based on the multigenic nature of cancer it should be expected that
there must be several genetic alterations in a single tumour. These
alterations might have occurred with an order of selection
depending on the stage where their phenotypic consequences are
required for the development and progression of the carcinomas.
The genetic analysis of CC in this context is rather limited. But
there is enough information pointing to the multigenic nature of
the process. In addition to viral DNA integration is present in allThe molecular genetics of cervical carcinoma 2015
British Journal of Cancer (1999) 80(12), 2008–2018 © 1999 Cancer Research Campaign
CC (Bosch et al, 1995). Two studies have detected multiple LOH
in several tumours (Mitra et al, 1994a; Mullokandov et al, 1996).
The number of LOH per tumour ranged from one to ten, with an
average number of four and a standard deviation of two, for 52
cases (Mitra et al, 1994a). Some of the locations appear consis-
tently in independent studies, but two of them are particularly
striking, those occurring in chromosomes 3 and 11. Also, some of
these LOH regions coincide with reported regions of HPV DNA
integration as is the case for chromosome regions 5p, 3p and 8q. In
the HeLa cell line there are alterations in four oncogenic regions,
5p11–15, 8q24, 9q31–34 and 22q12–13, surprisingly all of them
with integrated viral DNA (Popescu and DiPaolo, 1989). A very
recent study using CGH has detected some of these combinations
of genetic alterations in different types of cervical lesions
(Kirchhoff et al, 1999).
In experimental immortalization of human keratinocytes with
HPV 16 and HPV 18 there is LOH at chromosome region 3p
(Montgomery et al, 1995; Steenbergen et al, 1996), which is
combined with losses at chromosome arms 11q, 18q or 10p
(Steenbergen et al, 1996), some of which have also been detected
in primary tumours.
Other factors: genetic predisposition, the role of the
HLA system
In the pathogenesis of HPV-infected cells there are several aspects
that appear to be a consequence of the host immune response, such
as the reversion of lesions. The study of HLA haplotypes in a case
control study has demonstrated that in CIN II–III lesions certain
class II haplotypes, such as DQA1*0102 and DQB1*0602, are
overrepresented (Helland et al, 1998b). Considering the wide-
spread HPV-infected population, this observation might mean that
certain haplotypes might be more efficient than others in
triggering a host response that will eliminate the HPV-infected
cells. The overrepresented HLA alleles may be those that are less
effective in triggering a response against the HPV-infected cell.
Thus, the HPV infection that is highly prevalent starts to skew the
representation of HLA alleles as the disease progresses. This
might be a reflection of the host immune response to the presence
of HPV. Therefore, the HLA haplotype is an important factor at the
initial stage of the disease because it influences the point between
reversion and progression of the HPV-induced lesion. Further-
more, in CC there is a down-regulation of class I antigens in
tumour cells, thus minimizing the consequences of a possible 
anti-tumour cell-mediated response by the host immune system
(Bartholomew et al, 1997).
The host immune response can also be influenced by the type of
viral antigens that might be produced during disease progression.
In the initial infection with possible production of viral particles,
the main viral antigens are likely to be derived from the L1 and L2
capsid proteins. However, in CC with integrated HPV DNA, the
viral L1 and L2 genes are lost, and the epitopes available will be
derived from the intracellular expression of the viral E6 and E7
proteins. Thus, depending on the stage of the disease, the type of
host immune response directed against HPV-containing cells is
likely to be different. These differential viral protein expressions
will have to be taken into account for the design of HPV vaccines.
In lesions with integrated viral DNA and consequent loss of viral
L1 and L2 genes, the immune response will have to be against
peptides derived from the E6 and E7 viral proteins.
GENETIC DAMAGE AND CERVICAL LESION
STAGING
The ultimate goal of the identification of genetic damage implicated
in CC would be to understand its role within the biology of this
tumour phenotype and to translate this information in such a way
that at diagnosis stage one could predict the evolution and outcome
of the tumour depending on the mutations detected. At this moment
few specific LOH have been correlated with any particular stage
(Figure 2), but it is expected that in a few years, instead of LOH we
will be talking about specific genes and particular tumour cell prop-
erties. Today, some of the genetic damage can be correlated with
some stages along the progression of the lesion, thus indicating the
stage for which their phenotypic contribution is important. Some
genetic alterations such as viral DNA integration, presence of an
isochromosome i(5p), 3q amplification and LOH at 3p13–21 and
11q23 are important contributors for the development of an invasive
carcinoma. The timing of these genetic alterations is presented in
Figure 2. The day that specific mutations can be identified routinely
in a clinical setting is likely to improve the management of specific
tumour types because of its potentially predictable value.
Few studies have so far addressed the possible correlation
between LOH and tumour stage and evolution. For example, LOH
at 11q23 appears to correlate with extensive lymphovascular space
invasion, and these tumours tend to recur (Huettner et al, 1998),
and tumours with LOH on 18q have a relatively poor survival
(Kersemaekers et al, 1998b).
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Figure 2 Possible outcomes of HPV-infected cells. At the sequential stages
of the pathogenic process of cervical carcinoma different types of specific
genetic alterations are indicated. These alterations will be important for the
progression of the lesion to a more advanced clinical stage2016 PA Lazo
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The next step will be to identify which gene in each chromo-
some region is the relevant one for cervical carcinoma, and to
determine at what stage of tumour development they contribute.
Thus they will become markers of specific properties related to
tumour progression, and this knowledge we hope will contribute to
improve management of the patients.
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